keyword
MENU ▼
Read by QxMD icon Read
search

metastatic prostate cancer

keyword
https://www.readbyqxmd.com/read/28454349/low-serum-testosterone-is-associated-with-tumor-aggressiveness-and-poor-prognosis-in-prostate-cancer
#1
Huakang Tu, Jian Gu, Qing H Meng, Jeri Kim, Sara Strom, John W Davis, Yonggang He, Elizabeth A Wagar, Timothy C Thompson, Christopher J Logothetis, Xifeng Wu
Serum testosterone is a potential marker to distinguish between indolent and aggressive prostate cancer (PCa). The present study aimed to investigate whether low levels of total serum testosterone at diagnosis were associated with aggressive PCa and poor clinical outcomes. In total, 762 non-Hispanic Caucasian men with previously untreated PCa were recruited from The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Patients were categorized into three groups based on their total serum testosterone levels according to clinical guidelines [low (<230 ng/dl), intermediate (230-350 ng/dl) and normal (>350 ng/dl)]...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454286/suspected-tumor-to-meningioma-metastasis-a-case-report
#2
Iuri Santana Neville, Davi Fontoura Solla, Arthur Maynart Oliveira, Cesar Casarolli, Manoel Jacobsen Teixeira, Wellingson Silva Paiva
Tumor-to-meningioma metastasis (TMM) is a fairly uncommon phenomenon. Only 7 cases of prostate cancer with TMM have previously been described in the literature. The present study aimed to report a case of prostate cancer TMM, and to discuss the relevant clinical and neuroimaging aspects of this condition. A 68-year-old patient presented with headaches, poor visual acuity in the left eye and ipsilateral eyelid droop 3 years after a Simpson II resection of a left sphenoid wing meningioma. Computed tomography revealed a hyperdense area suggestive of a recurrent left sphenoid wing meningioma...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28453693/racial-disparities-in-prostate-cancer-outcome-among-prostate-specific-antigen-screening-eligible-populations-in-the-united-states
#3
B A Mahal, Y-W Chen, V Muralidhar, A R Mahal, T K Choueiri, K E Hoffman, J C Hu, C J Sweeney, J B Yu, F Y Feng, S P Kim, C J Beard, N E Martin, Q-D Trinh, P L Nguyen
Background: In 2012, the United States Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen (PSA) screening, despite evidence that Black men are at a higher risk of prostate cancer-specific mortality (PCSM). We evaluated whether Black men of potentially screening-eligible age (55-69 years) are at a disproportionally high risk of poor outcomes. Patients and methods: The SEER database was used to study 390 259 men diagnosed with prostate cancer in the United States between 2004 and 2011...
May 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28447314/inhibition-of-the-insulin-like-growth-factor-1-receptor-potentiates-acute-effects-of-castration-in-a-rat-model-for-prostate-cancer-growth-in-bone
#4
Annika Nordstrand, Sofia Halin Bergström, Elin Thysell, Erik Bovinder-Ylitalo, Ulf H Lerner, Anders Widmark, Anders Bergh, Pernilla Wikström
Prostate cancer (PCa) patients with bone metastases are primarily treated with androgen deprivation therapy (ADT). Less pronounced ADT effects are seen in metastases than in primary tumors. To test if acute effects of ADT was enhanced by concurrent inhibition of pro-survival insulin-like growth factor 1 (IGF-1), rats were inoculated with Dunning R3327-G tumor cells into the tibial bone marrow cavity and established tumors were treated with castration in combination with IGF-1 receptor (IGF-1R) inhibitor NVP-AEW541, or by each treatment alone...
April 26, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/28446230/label-retention-and-stem-cell-marker-expression-in-the-developing-and-adult-prostate-identifies-basal-and-luminal-epithelial-stem-cell-subpopulations
#5
Jens Adam Ceder, Tilly Wilhelmina Aalders, Jack Antonius Schalken
BACKGROUND: Prostate cancer is the second most frequent cancer among males worldwide, and most patients with metastatic disease eventually develop therapy-resistant disease. Recent research has suggested the existence of cancer stem-like cells, and that such cells are behind the therapy resistance and progression. METHODS: Here, we have taken advantage of the relatively quiescent nature of stem cells to identify the slow-cycling label-retaining stem cell (LRC) populations of the prostate gland...
April 26, 2017: Stem Cell Research & Therapy
https://www.readbyqxmd.com/read/28445962/psma-homing-dsrna-chimeric-protein-vector-kills-prostate-cancer-cells-and-activates-anti-tumor-bystander-responses
#6
Yael Langut, Nufar Edinger, Efrat Flashner-Abramson, Naomi Melamed-Book, Mario Lebendiker, Yael Levi-Kalisman, Shoshana Klein, Alexander Levitzki
The treatment of metastatic androgen-resistant prostate cancer remains a challenge. We describe a protein vector that selectively delivers synthetic dsRNA, polyinosinic/polycytidylic acid (polyIC), to prostate tumors by targeting prostate specific membrane antigen (PSMA), which is overexpressed on the surface of prostate cancer cells.The chimeric protein is built from the double stranded RNA (dsRNA) binding domain of PKR tethered to a single chain anti-PSMA antibody. When complexed with polyIC, the chimera demonstrates selective and efficient killing of prostate cancer cells...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28444227/incidence-and-prognosis-of-patients-with-brain-metastases-at-diagnosis-of-systemic-malignancy-a-population-based-study
#7
Daniel N Cagney, Allison M Martin, Paul J Catalano, Amanda J Redig, Nancy U Lin, Eudocia Q Lee, Patrick Y Wen, Ian F Dunn, Wenya Linda Bi, Stephanie E Weiss, Daphne A Haas-Kogan, Brian M Alexander, Ayal A Aizer
Background: Brain metastases are associated with significant morbidity and mortality. Population-level data describing the incidence and prognosis of patients with brain metastases are lacking. The aim of this study was to characterize the incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy using recently released data from the Surveillance, Epidemiology, and End Results (SEER) program. Methods: We identified 1,302,166 patients diagnosed with non-hematologic malignancies originating outside of the central nervous system between 2010-2013 and described the incidence proportion and survival of patients with brain metastases...
April 24, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28443152/supplementary-data-maximal-testosterone-suppression-in-the-management-of-recurrent-and-metastatic-prostate-cancer
#8
REVIEW
Laurence Klotz, Rodney H Breau, Loretta L Collins, Martin E Gleave, Tom Pickles, Frederic Pouliot, Fred Saad
No abstract text is available yet for this article.
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28443139/maximal-testosterone-suppression-in-the-management-of-recurrent-and-metastatic-prostate-cancer
#9
REVIEW
Laurence Klotz, Rodney H Breau, Loretta L Collins, Martin E Gleave, Tom Pickles, Frederic Pouliot, Fred Saad
INTRODUCTION: Testosterone suppression, or androgen-deprivation therapy (ADT), is an established treatment for recurrent and metastatic prostate cancer (PCa). Based on the accuracy and sensitivity of early assays (c. 1960-1970), the castrate testosterone level was set at ≤1.7 nmol/l. Improved sensitivity of testosterone assays shows that both surgical and medical castration can achieve levels <0.7 nmol/l. However, the clinical implications and importance of maximum testosterone suppression remains a subject of controversy...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28441368/skeletal-scintigraphy
#10
Jaime L Montilla-Soler, Rikesh Makanji
BACKGROUND: Skeletal scintigraphy remains a valuable tool in the initial and subsequent evaluation of the skeletal system in patients with a diagnosis of primary or metastatic neoplasms. METHODS: We discuss radiopharmaceuticals, nuclear medicine imaging techniques, and current as well as future oncological applications in the adult population. Pertinent literature was reviewed to describe the advantages and limitations of available technologies for the evaluation of skeletal metastatic disease...
April 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28441112/second-line-hormonal-therapy-for-men-with-chemotherapy-na%C3%A3-ve-castration-resistant-prostate-cancer-american-society-of-clinical-oncology-provisional-clinical-opinion
#11
Katherine S Virgo, Ethan Basch, D Andrew Loblaw, Tom Oliver, R Bryan Rumble, Michael A Carducci, Luke Nordquist, Mary-Ellen Taplin, Eric Winquist, Eric A Singer
Purpose ASCO provisional clinical opinions (PCOs) offer direction to the ASCO membership after publication or presentation of potential practice-changing data. This PCO addresses second-line hormonal therapy for chemotherapy-naïve men with castration-resistant prostate cancer (CRPC) who range from being asymptomatic with only biochemical evidence of CRPC to having documented metastases but minimal symptoms. Clinical Context The treatment goal for CRPC is palliation. Despite resistance to initial androgen deprivation therapy, most men respond to second-line hormonal therapies...
April 25, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28440432/ron-and-c-met-facilitate-metastasis-through-the-erk-signaling-pathway-in-prostate-cancer-cells
#12
Binbin Yin, Zhenping Liu, Yiyun Wang, Xuchu Wang, Weiwei Liu, Pan Yu, Xiuzhi Duan, Chunhua Liu, Yuhua Chen, Yurong Zhang, Xiaoyan Pan, Hangping Yao, Zhaoping Liao, Zhihua Tao
Prostate cancer (PCa) is a metastatic malignant cancer driven by complex pathological mechanisms and characterized by poor long-term prognosis. Metastasis is the main cause of death of PCa patients, yet the molecular mechanisms of this process are poorly understood. In the present study, positive co-expression of RON and c-Met was observed in human clinical PCa tissues (biopsy material), as detected by immunohistochemical staining and quantitative real-time PCR. We investigated this further in PCa cells, demonstrating that the inhibition of RON and c-Met with foretinib (GSK1363089) suppressed metastasis and promoted the reversal of the epithelial-to-mesenchymal transition (EMT) in PCa cells...
April 19, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28440324/lutetium-177-labelled-anti-prostate-specific-membrane-antigen-antibody-and-ligands-for-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-a-systematic-review-and-meta-analysis
#13
R J S Calopedos, V Chalasani, R Asher, L Emmett, H H Woo
BACKGROUND: Promising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 ((177)Lu). We performed a systematic review and meta-analysis to assess the therapeutic response of (177)Lu-PSMA in the treatment of metastatic castration-resistant prostate cancer (mCRPC). METHODS: A systematic review was conducted using electronic databases up to December 2016. Two reviewers independently extracted data and assessed methodological quality...
April 25, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28440321/association-of-comorbid-disease-burden-at-diagnosis-with-higher-tumor-grade-in-men-with-non-metastatic-prostate-cancer
#14
T J Daskivich, C J Dru, D Skarecky, T Ahlering, S J Freedland
BACKGROUND: While older age is associated with higher tumor grade, it is unknown whether comorbid disease burden has a similar, independent association. We sought to evaluate the impact of comorbid disease burden on tumor grade at diagnosis as indicated by biopsy Gleason score. METHODS: We conducted an observational cohort study of 1260 men newly diagnosed with non-metastatic prostate cancer from 1998 to 2004 at two Veterans Affairs Medical Centers. Multivariable ordinal and multinomial logistic regression were used to evaluate the association between Charlson Comorbidity Index score and biopsy Gleason score...
April 25, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28440320/a-review-of-pomegranate-in-prostate-cancer
#15
REVIEW
C J Paller, A Pantuck, M A Carducci
BACKGROUND: Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials. METHODS: Trials targeted patients on active surveillance, neoadjuvant patients, patients with biochemical recurrence (BCR) following local therapy for prostate cancer, and patients with metastatic castration-resistant prostate cancer (mCRPC)...
April 25, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28440262/risk-of-complications-and-urinary-incontinence-following-cytoreductive-prostatectomy-a-multi-institutional-study
#16
Dae Keun Kim, Jaspreet Singh Parihar, Young Suk Kwon, Sinae Kim, Brian Shinder, Nara Lee, Nicholas Farber, Thomas Ahlering, Douglas Skarecky, Bertram Yuh, Nora Ruel, Wun-Jae Kim, Koon Ho Rha, Isaac Yi Kim
Emerging evidence has suggested that cytoreductive prostatectomy (CRP) allows superior oncologic control when compared to current standard of care androgen deprivation therapy alone. However, the safety and benefit of cytoreduction in metastatic prostate cancer (mPCa) has not been proven. Therefore, we evaluated the incidence of complications following CRP in men newly diagnosed with mPCa. A total of 68 patients who underwent CRP from 2006 to 2014 at four tertiary surgical centers were compared to 598 men who underwent radical prostatectomy for clinically localized prostate cancer (PCa)...
April 25, 2017: Asian Journal of Andrology
https://www.readbyqxmd.com/read/28438626/near-infrared-intraoperative-molecular-imaging-can-identify-metastatic-lymph-nodes-in-prostate-cancer
#17
Leilei Xia, Ryan Zeh, Jack Mizelle, Andrew Newton, Jarrod Predina, Shuming Nie, Sunil Singhal, Thomas J Guzzo
OBJECTIVE: To propose a novel method to perform indocyanine green (ICG) based near-infrared (NIR) fluorescence imaging during pelvic lymph node dissection (PLND) for prostate cancer patients with lymph node metastasis (LNM). MATERIALS AND METHODS: A prostate cancer cell line PC3 was used to establish xenograft model in NOD/SCID mouse. After tumor growth, mice were injected through the tail vein with ICG. Xenografts and surrounding tissues were imaged with NIR camera 24 hours after intravenous ICG and tumor-to-background ratios (TBRs) were calculated...
April 21, 2017: Urology
https://www.readbyqxmd.com/read/28437789/comparative-proteomics-uncovers-correlated-signaling-network-and-potential-biomarkers-for-progression-of-prostate-cancer
#18
Jianzhong Ai, Yi Lu, Qiang Wei, Hong Li
BACKGROUND/AIMS: Prostate cancer is one of the most common cancers for males worldwide, and it is prone to show the metastatic foci in lymph node and bone with high mortality. To date, the potential mechanism and the corresponding biomarkers for metastatic prostate cancer are still lacking. Hence, our study aims to clarify the mechanism of prostate cancer progression and identify the useful biomarkers for metastatic prostate cancer. METHODS: The proteins and network tightly associated with tumor metastasis were identified using quantitative proteomics...
January 10, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28437038/impact-of-preoperative-risk-on-metastatic-progression-and-cancer-specific-death-in-patients-with-adverse-pathology-at-radical-prostatectomy
#19
Katharina Boehm, Sami-Ramzi Leyh-Bannurah, Clemens Rosenbaum, Laurenz S Brandi, Lars Budäus, Markus Graefen, Hartwig Huland, Axel Haferkamp, Derya Tilki
OBJECTIVE: To evaluate the impact of preoperative risk category on metastatic disease (MetD) and prostate cancer mortality (CSM) in prostate cancer (PCa) patients with adverse pathology at radical prostatectomy (RP). PATIENTS AND METHODS: The records of 6943 patients who underwent radical prostatectomy (RP) in a European tertiary-center were analysed. Biochemical recurrence (BCR), MetD and CSM were assessed for patients with adverse pathology at RP and stratified according to preoperative low- vs...
April 24, 2017: BJU International
https://www.readbyqxmd.com/read/28436066/reduction-by-coffee-consumption-of-prostate-cancer-risk-evidence-from-the-moli-sani-cohort-and-cellular-models
#20
George Pounis, Claudio Tabolacci, Simona Costanzo, Martina Cordella, Marialaura Bonaccio, Livia Rago, Daniela D'Arcangelo, Augusto Filippo Di Castelnuovo, Giovanni de Gaetano, Maria Benedetta Donati, Licia Iacoviello, Francesco Facchiano
Meta-analytic data on the effect of coffee in prostate cancer risk are controversial. Caffeine as a bioactive compound of coffee has not yet been studied in deep in vitro. Our study aimed at evaluating in a population cohort the effect of Italian-style coffee consumption on prostate cancer risk and at investigating in vitro the potential antiproliferative and antimetastatic activity of caffeine on prostate cancer cell lines. 6,989 men of the Moli-sani cohort aged ≥50 years were followed for a mean of 4.24 ± 1...
April 24, 2017: International Journal of Cancer. Journal International du Cancer
keyword
keyword
30125
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"